Getting patients with progeria or processing-deficient progeroid laminopathies (PDPL) onto an appropriate dosage of Zokinvy matters.
Zokinvy is available in 50-mg and 75-mg capsules, which allows for flexible administration between starting and final dose. Recommended dosing is capsules twice daily with food.1
For patients with a BSA ≥ 0.39 m2, the starting dosage is 115 mg/m2 twice daily with morning and evening meals. An appropriate dosage strength of Zokinvy is not available for patients with a BSA below 0.39 m2.1
Increase the dosage to 150 mg/m2 twice daily. Round all total daily doses to the nearest 25-mg increment.1
Managing progeria and PDPL can be complicated. With Zokinvy, you have options.
Depending on the patient’s ability to swallow, Zokinvy can be taken alone or mixed with Ora-Blend SF®, Ora-Plus®, orange juice, or applesauce. Do not mix with any juice containing grapefruit or Seville oranges. Ensure that the mixture is taken within approximately 10 minutes of mixing.1
For unmanageable adverse reactions, dosing of Zokinvy can be reduced to the starting dosage (115 mg/m² twice daily).1
Loperamide is contraindicated in patients less than 2 years of age. When Zokinvy is coadministered with loperamide, do not exceed loperamide 1 mg once daily when first coadministered. Slowly increase loperamide dosage with caution in accordance with its approved product labeling.1
Discontinue Zokinvy for 10 to 14 days before and 2 days after administration of midazolam.1
Eiger OneCare™ helps patients and their caregivers with access to a dedicated, specialized team. Each member of this team is focused on the care and needs of patients with progeria or PDPL. Download an enrollment form to start
IMPORTANT SAFETY INFORMATION
ZOKINVY is contraindicated in patients taking:
INDICATION AND USAGE
ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: